Posted by Michael Wonder on 24 Aug 2016
NICE issues draft guidance on the use of Eylea (afilbercept)
24 August 2016 - NICE has issued draft final guidance on the use of Bayer's Eylea (aflibercept) on the NHS.
Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion, only if the company provides aflibercept with the discount agreed in the patient access scheme.
